Trial reportMetabolic brain disease2026
Beyond mobility: A prospective study on diet and metabolism in hereditary spastic paraplegia.
Trial report in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolism plays an important role in neurodegenerative diseases. Hereditary spastic paraplegias (HSP) are a heterogeneous group of rare genetic neurodegenerative disorders, commonly characterized by the clinical syndrome of progressive lower limb spasticity and mobility loss. Obesity has been linked to distinct genotypes, but the role of metabolism and nutrition in HSP remains unclear.We aimed to To evaluate metabolism and nutrition in specific HSP genotypes and to assess the impact of nutritional counseling on disease progression and body composition. In this prospective explorative pilot study, we assessed the neurological, metabolic and nutritional status of patients with HSP at baseline and one year after nutritional counseling. A total of 36 patients with genetically confirmed SPG4-, SPG7- and SPG11-associated HSP were recruited. BMI in SPG4 and SPG7 was comparable to healthy population data, whereas SPG11 showed significantly higher BMI (+ 22.9%, p < 0.05) with a considerable interindividual variability. Across all genotypes, disease severity according to the Spastic Paraplegia Rating Scale correlated negatively with leg muscle mass (ρ = -0.39, p < 0.05), protein (ρ = -0.35, p < 0.05) and fiber intake (ρ = -0.41, p < 0.05). After one year, there was a significant loss of relative muscle mass (-7.2%, p < 0.001). Progressive loss of muscle mass in HSP asks for an effective nutritional intervention combined with exercise in order to influence disease progression in HSP. The SPG11-associated obese phenotype may evolve with disease progression due to multifactorial metabolic changes, beyond reduced mobility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.